Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2014 2
2015 2
2016 2
2017 2
2018 2
2019 2
2020 6
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Botta C, Perez C, Larrayoz M, Puig N, Cedena MT, Termini R, Goicoechea I, Rodriguez S, Zabaleta A, Lopez A, Sarvide S, Blanco L, Papetti DM, Nobile MS, Besozzi D, Gentile M, Correale P, Siragusa S, Oriol A, González-Garcia ME, Sureda A, de Arriba F, Rios Tamayo R, Moraleda JM, Gironella M, Hernandez MT, Bargay J, Palomera L, Pérez-Montaña A, Goldschmidt H, Avet-Loiseau H, Roccaro A, Orfao A, Martinez-Lopez J, Rosiñol L, Lahuerta JJ, Blade J, Mateos MV, San-Miguel JF, Martinez Climent JA, Paiva B; Programa Para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) cooperative group; iMMunocell study group. Botta C, et al. Among authors: goicoechea i. Nat Commun. 2023 Sep 20;14(1):5825. doi: 10.1038/s41467-023-41562-6. Nat Commun. 2023. PMID: 37730678 Free PMC article.
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V, Roa S, Goicoechea I, Maia C, Lasaga M, Chesi M, Bergsagel PL, Larrayoz MJ, Calasanz MJ, Campos-Sanchez E, Martinez-Cano J, Panizo C, Rodriguez-Otero P, Vicent S, Roncador G, Gonzalez P, Takahashi S, Katz SG, Walensky LD, Ruppert SM, Lasater EA, Amann M, Lozano T, Llopiz D, Sarobe P, Lasarte JJ, Planell N, Gomez-Cabrero D, Kudryashova O, Kurilovich A, Revuelta MV, Cerchietti L, Agirre X, San Miguel J, Paiva B, Prosper F, Martinez-Climent JA. Larrayoz M, et al. Among authors: goicoechea i. Nat Med. 2023 Mar;29(3):632-645. doi: 10.1038/s41591-022-02178-3. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928817 Free PMC article.
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Nevone A, Girelli M, Mangiacavalli S, Paiva B, Milani P, Cascino P, Piscitelli M, Speranzini V, Cartia CS, Benvenuti P, Goicoechea I, Fazio F, Basset M, Foli A, Nanci M, Mazzini G, Caminito S, Sesta MA, Casarini S, Rognoni P, Lavatelli F, Petrucci MT, Olimpieri PP, Ricagno S, Arcaini L, Merlini G, Palladini G, Nuvolone M. Nevone A, et al. Among authors: goicoechea i. Leukemia. 2022 Aug;36(8):2076-2085. doi: 10.1038/s41375-022-01599-w. Epub 2022 May 24. Leukemia. 2022. PMID: 35610346 Free article.
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.
Guerrero C, Puig N, Cedena MT, Goicoechea I, Perez C, Garcés JJ, Botta C, Calasanz MJ, Gutierrez NC, Martin-Ramos ML, Oriol A, Rios R, Hernandez MT, Martinez-Martinez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Mosquera-Orgueira A, Gonzalez-Perez MS, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B. Guerrero C, et al. Among authors: goicoechea i. Clin Cancer Res. 2022 Jun 13;28(12):2598-2609. doi: 10.1158/1078-0432.CCR-21-3430. Clin Cancer Res. 2022. PMID: 35063966
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.
Rodriguez S, Celay J, Goicoechea I, Jimenez C, Botta C, Garcia-Barchino MJ, Garces JJ, Larrayoz M, Santos S, Alignani D, Vilas-Zornoza A, Perez C, Garate S, Sarvide S, Lopez A, Reinhardt HC, Carrasco YR, Sanchez-Garcia I, Larrayoz MJ, Calasanz MJ, Panizo C, Prosper F, Lamo-Espinosa JM, Motta M, Tucci A, Sacco A, Gentile M, Duarte S, Vitoria H, Geraldes C, Paiva A, Puig N, Garcia-Sanz R, Roccaro AM, Fuerte G, San Miguel JF, Martinez-Climent JA, Paiva B. Rodriguez S, et al. Among authors: goicoechea i. Sci Adv. 2022 Jan 21;8(3):eabl4644. doi: 10.1126/sciadv.abl4644. Epub 2022 Jan 19. Sci Adv. 2022. PMID: 35044826 Free PMC article.
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.
Alameda D, Goicoechea I, Vicari M, Arriazu E, Nevone A, Rodriguez S, Lasa M, Puig N, Cedena MT, Alignani D, Garate S, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Ocio EM, Lecumberri R, Garcia de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Perez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Fazio VM, Martinez-Lopez J, Lahuerta JJ, Mateos MV, Odero MD, Prosper F, Weiner A, Amit I, Nuvolone M, San Miguel JF, Paiva B. Alameda D, et al. Among authors: goicoechea i. Blood. 2021 Oct 28;138(17):1583-1589. doi: 10.1182/blood.2020009754. Blood. 2021. PMID: 34133718 Free article.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Goicoechea I, Puig N, Cedena MT, Burgos L, Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MM, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodriguez I, Sarvide S, Alameda D, Garcés JJ, Rodriguez S, Fresquet V, Celay J, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Rios R, Martin-Sanchez J, Martinez-Martinez R, Sarra J, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Martinez-Climent JA, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel J, Paiva B. Goicoechea I, et al. Blood. 2021 Jan 7;137(1):49-60. doi: 10.1182/blood.2020006731. Blood. 2021. PMID: 32693406 Free article. Clinical Trial.
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
Garcés JJ, Bretones G, Burgos L, Valdes-Mas R, Puig N, Cedena MT, Alignani D, Rodriguez I, Puente DÁ, Álvarez MG, Goicoechea I, Rodriguez S, Calasanz MJ, Agirre X, Flores-Montero J, Sanoja-Flores L, Rodriguez-Otero P, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Pérez-Montaña A, El Omri H, Prosper F, Mateos MV, Rosiñol L, Blade J, Lahuerta JJ, Orfao A, Lopez-Otin C, San Miguel JF, Paiva B; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Garcés JJ, et al. Among authors: goicoechea i. Leukemia. 2020 Nov;34(11):3007-3018. doi: 10.1038/s41375-020-0883-0. Epub 2020 Jun 1. Leukemia. 2020. PMID: 32475991
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, Alameda D, San José-Eneriz E, Merino J, Rodríguez-Otero P, Maia C, Alignani D, Maiso P, Manrique I, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Riillo C, Rossi M, Rosiñol L, Oriol A, Blanchard MJ, Rios R, Sureda A, Martin J, Martinez R, Bargay J, de la Rubia J, Hernandez MT, Martinez-Lopez J, Orfao A, Agirre X, Prosper F, Mateos MV, Lahuerta JJ, Blade J, San-Miguel JF, Paiva B. Perez C, et al. Among authors: goicoechea i. Blood. 2020 Jul 9;136(2):199-209. doi: 10.1182/blood.2019004537. Blood. 2020. PMID: 32325491 Free article. Clinical Trial.
24 results